For Industry

Public Meeting on Patient-Focused Drug Development for Hereditary Angioedema

On September 25, 2017, FDA is conducting a public meeting on Patient-Focused Drug Development for Hereditary Angioedema. FDA is interested in obtaining patient and caregiver perspectives on the on the impact of Hereditary Angioedema on daily life and patient views on treatment approaches.

Date:

September 25, 2017

Time:

9:00 a.m. - 3:00 p.m.

Location:

FDA White Oak Campus
10903 New Hampshire Ave.
Bldg. 31 Conference Center
The Great Room (Rm. 1503)
Silver Spring, MD 20993

Registration:

To register for this meeting, visit: https://www.eventbrite.com/e/patient-focused-drug-development-for-hereditary-angioedema-public-meeting-tickets-32300298061 website.

Registration to attend the meeting must be received by August 31, 2017.

Webcast Information:

Public Docket:

In addition to providing input at the public meeting, stakeholders are invited to provide their perspectives on the discussion questions through the public docket. The docket closes on November 20, 2017.

FDA is interested in patient responses to the questions listed in the Federal Register Notice: https://www.federalregister.gov/documents/2017/07/20/2017-15202/patient-focused-drug-development-for-hereditary-angioedema-public-meeting-request-for-comments

Access the public docket here: https://www.regulations.gov

Page Last Updated: 07/21/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English